Search

Displaying results 5691 - 5700 of 10000 in total
  1. Drug

    Zedenoleucel

    go.drugbank.com/drugs/DB18639
    Investigational

    MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.

  2. Drug

    Lixudebart

    go.drugbank.com/drugs/DB19244
    Investigational

    Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]

  3. Drug

    H-151

    go.drugbank.com/drugs/DB29149
    Experimental

    H-151 is an inhibitor of the stimulator of interferon genes (STING) protein.

  4. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  5. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  6. Drug

    Col-Treg

    go.drugbank.com/drugs/DB18451
    Experimental

    Col-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]

    Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagen
  7. Drug

    RCT1100

    go.drugbank.com/drugs/DB18830
    Investigational

    RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]

  8. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  9. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

  10. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    ’s and Schizophrenia, an unmet medical need. … SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

    Categories: Serotonin Receptor Antagonists